Charles Matine serves as Executive at Bionik Laboratories Corp., where they oversee executive responsibilities. Since joining the company, Charles Matine has executed 2 insider transactions totaling $108.3K, demonstrating a bullish approach to their equity position. Their most recent transaction on Jun 9, 2023 involved purchasing 180,555 shares valued at $108.3K.
Charles Matine currently holds 206,985 shares of Bionik Laboratories Corp. (BNKL), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Charles Matine has been a net buyer of BNKL stock. They have purchased $108.3K and sold $0 worth of shares.
Charles Matine's most recent insider trade was on Jun 9, 2023, when they purchased 180,555 shares at $0.60 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |